FDA Approves Abbott's Bioresorbable Stent for CAD

Deborah Brauser


July 05, 2016

SILVER SPRING, MD — The US Food and Drug Administration (FDA) has approved the Absorb GT1 Bioresorbable Vascular System (Abbott Vascular), with the first absorbable stent for coronary artery disease.[1]

The news isn't entirely surprising since, as reported by heartwire from Medscape, an FDA advisory panel in March was almost unanimous in its support for the device. Nine members of the Circulatory System Devices panel vs one voted that it was safe, and nine to zero voted that it had an acceptable risk/benefit profile, with one member abstaining. In addition, all 10 members voted that it was effective.

Today's approval was based on the ABSORB III trial of more than 2000 patients randomly assigned to the Absorb GT1 or a conventional everolimus-eluting cobalt-chromium stent (Xience, Abbott Vascular).

The findings, which were first presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2015 meeting, showed that the two devices had a clinically similar rate of target lesion failure (a composite of cardiac death, target vessel myocardial infarction, or target lesion revascularization) at 1 year (7.8% vs 6.1%, respectively). Also not significant was the between-group difference in rates of device thrombosis (1.5% vs 0.7%).

The FDA noted that potential treatment-related adverse events from the Absorb GT1 include allergic reactions, infection at the insertion site, internal bleeding, and other "coronary artery complications."

Still, today's approval "offers a new treatment option for individuals who are candidates for angioplasty but would prefer an absorbable device rather than a permanent metallic coronary stent," Dr Bram Zuckerman (Center for Devices and Radiological Health, FDA) said in the agency's release.

Within about 3 years, the poly(L-lactide) stent is completely absorbed into the body.

In its own release,[2] Abbott noted that the device is currently available in more than 100 countries. Its plan for the US is to offer it first to the interventional cardiology centers that participated in its clinical trials and then to other hospitals.

Follow Deborah Brauser on Twitter: @heartwireDeb. For more from theheart.org, follow us on Twitter and Facebook.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.